# US 2026/0207689 A1 · Prostate neoantigens and their uses

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0207689 A1
- Document ID: US20260207689A1
- Status: Published application
- Kind: A1
- Application number: 19/530,943
- Filed: 2026-02-05
- Published: 2026-07-23
- Earliest claimed: 2019-01-10
- Applicants: Jansen Biotech, Inc.
- Inventors: Kurtis E. Bachman; Vipul Bhargava; Darryl L. Davis; Vinod Krishna; Guido Leoni; David Pocalyko; Pegah Safabakhsh; Manuel Sepulveda; Derick Siegel; Marco Gottardis
- Web page: https://patentgrep.com/patent/US20260207689A1

## CPC

- A61K 35/761: Adenovirus
- A61K 39/0011: {Cancer antigens}
- A61K 39/001193: {Prostate associated antigens e.g. Prostate stem cell antigen [PSCA]; Prostate carcinoma tumor antigen [PCTA]; PAP or PSGR}
- A61K 39/001194: {Prostate specific antigen [PSA]}
- A61K 39/001195: {Prostate specific membrane antigen [PSMA]}
- A61P 35/00: Antineoplastic agents
- C07K 14/4748: {Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE}
- C07K 16/3069: {Reproductive system, e.g. ovaria, uterus, testes, prostate}
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61K 2039/51: {comprising whole cells, viruses or DNA/RNA}
- A61K 2039/5256: {expressing foreign proteins}
- A61K 2039/53: {DNA (RNA) vaccination}
- A61K 2039/545: {characterised by the dose, timing or administration schedule}
- A61K 2039/572: {cytotoxic response}
- A61K 2039/70: {Multivalent vaccine}
- A61K 2039/884: {prostate}
- C12N 2710/10343: viral genome or elements thereof as genetic vector
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

The disclosure relates to prostate neoantigens, polynucleotides encoding them, vectors, host cells, recombinant virus particles, vaccines comprising the neoantigens, proteinaceous molecules binding the prostate neoantigens, and methods of making and using them.

## Claims

### Claim 1

A heterologous polypeptide comprising the amino acid sequences of SEQ ID NOs: 275, 381, 333, 337, 269, 253, 309, 325, 271, 305, 251, 245, 261, 265, 317, 255, 297, 285, 437, 439, 442, 444, 379, 343, 211, 349, 213, 215, 221, 219, 225, 345, 353, 235, 223, 167, 171, 19, 23, and 177.

### Claim 2 (depends on 1)

The heterologous polypeptide of claim 1, comprising one or more reverse peptide bonds, D-isomers of amino acids, chemical modifications, or any combination thereof.

### Claim 3 (depends on 1)

A vaccine comprising the heterologous polypeptide of claim 1.

### Claim 4 (depends on 1)

A heterologous polynucleotide encoding the heterologous polypeptide of claim 1.

### Claim 5 (depends on 4)

The heterologous polynucleotide of claim 4, comprising the polynucleotide sequences of SEQ ID NOs: 276, 382, 334, 338, 270, 254, 310, 326, 272, 306, 252, 246, 262, 266, 318, 256, 298, 286, 448, 450, 453, 455, 380, 344, 212, 350, 214, 216, 222, 220, 226, 346, 354, 236, 224, 168, 172, 20, 24, and 178.

### Claim 6

A vector comprising the heterologous polynucleotide of 5.

### Claim 7 (depends on 6)

A vaccine comprising the vector of claim 6.

### Claim 8 (depends on 7)

The vaccine of claim 7, wherein the heterologous polynucleotide comprises a promoter, an enhancer, a polyadenylation site, a Kozak sequence, a stop codon, a T cell enhancer (TCE), or any combination thereof.

### Claim 9 (depends on 8)

The vaccine of claim 8, wherein the promoter comprises a CMV promoter or a vaccinia P7.5 promoter.

### Claim 10 (depends on 9)

The vaccine of claim 9, wherein the TCE comprises the polynucleotide sequence of SEQ ID NO: 546, the CMV promoter comprises the polynucleotide sequence of SEQ ID NO: 628, the vaccinia P7.5 promoter comprises the polynucleotide sequence of SEQ ID NO: 630, and the polyadenylation site comprises a bovine growth hormone polyadenylation site comprising the polynucleotide sequence of SEQ ID NO: 629.

### Claim 11 (depends on 5)

The vaccine of claim 5, wherein the heterologous polynucleotide is DNA or RNA.

### Claim 12 (depends on 11)

The vaccine of claim 11, wherein the RNA is mRNA or self-replicating RNA.

### Claim 13 (depends on 7)

The vaccine of claim 7, wherein the vaccine is a recombinant virus.

### Claim 14 (depends on 13)

The vaccine of claim 13, wherein the recombinant virus is derived from adenovirus (Ad), poxvirus, adeno-associated virus (AAV) or retrovirus.

### Claim 15 (depends on 14)

The vaccine of claim 14, wherein the recombinant viral vector is derived from hAd5, hAd7, hAd11, hAd26, hAd34, hAd35, hAd48, hAd49, hAd50, GAd20, GAd19, GAd21, GAd25, GAd26, GAd27, GAd28, GAd29, GAd30, GAd31, ChAd3, ChAd4, ChAd5, ChAd6, ChAd7, ChAd8, ChAd9, ChAd10, ChAd11, ChAd16, ChAd17, ChAd19, ChAd20, ChAd22, ChAd24, ChAd26, ChAd30, ChAd31, ChAd37, ChAd38, ChAd44, ChAd55, ChAd63, ChAd73, ChAd82, ChAd83, ChAd146, ChAd147, PanAd1, PanAd2, PanAd3, Copenhagen vaccinia virus, New York Attenuated Vaccinia Virus (NYVAC), ALVAC, TROVAC, or MVA.

### Claim 16 (depends on 15)

The vaccine of claim 15, wherein the recombinant virus is derived from GAd20.

### Claim 17 (depends on 15)

The vaccine of claim 15, wherein the recombinant virus is derived from MVA.

### Claim 18 (depends on 3)

A pharmaceutical composition comprising the vaccine of claim 3 and a pharmaceutically acceptable carrier or adjuvant.

### Claim 19 (depends on 7)

A pharmaceutical composition comprising the vaccine of claim 7 and a pharmaceutically acceptable carrier or adjuvant.

### Claim 20 (depends on 3)

A method of inducing an immune response in a subject, the method comprising administering to the subject the vaccine of claim 3.

### Claim 21 (depends on 7)

A method of inducing an immune response in a subject, the method comprising administering to the subject the vaccine of claim 7.
